Physician profile
Sherry L Stein
NPI 1134227895
$4,722.97
in general payments reported to CMS, 2019-2025
34 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $276 · 2021: $369 · 2022: $652 · 2023: $713 · 2024: $1,320 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,071.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $567.84 | 2021-2025 | Vraylar |
| Amgen INC. | $558.97 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $555.37 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $491.42 | 2020-2025 | |
| Novo Nordisk INC | $405.65 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $344.70 | 2019-2025 | Veozah, Myrbetriq |
| Dexcom, INC. | $270.04 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $176.53 | 2020-2024 | Farxiga |
| Radius Health, INC. | $146.55 | 2019-2025 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $128.23 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $119.31 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $98.76 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $98.39 | 2021-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $90.99 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Eisai INC. | $71.61 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $61.01 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $60.50 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $59.65 | 2022-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $57.95 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.76 | 2022 | |
| Axsome Therapeutics, INC. | $54.86 | 2024-2025 | Auvelity |
| Lexicon Pharmaceuticals, INC. | $41.11 | 2023-2024 | Inpefa |
| Amarin Pharma, INC. | $32.44 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.11 | 2019-2023 | Jardiance, Tradjenta |
| Medtronic, INC. | $19.54 | 2024 | Minimed 780g |
| Abbott Laboratories | $16.79 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $16.05 | 2024 | Uptravi, Opsumit |
| Ani Pharmaceuticals, INC. | $15.87 | 2025 | Purified Cortrophin Gel |
| Roche Diagnostics Corporation | $14.39 | 2020 | |
| Allergan, INC. | $13.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.46 | 2022 | |
| Phadia US INC. | $13.12 | 2022 | |
| Mylan Specialty L.P. | $12.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.